Halozyme Therapeutic (HALO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 12-2024 | 12-2023 | 12-2022 | 12-2021 | |
| Sales | 1,396,611 | 1,015,324 | 829,253 | 660,116 | 443,310 |
| Cost of Goods | 228,774 | 159,417 | 192,361 | 139,304 | 81,413 |
| Gross Profit | 1,167,837 | 855,907 | 636,892 | 520,812 | 361,897 |
| Operating Expenses | 699,605 | 304,849 | 299,679 | 253,585 | 86,408 |
| Operating Income | 469,006 | 551,475 | 337,574 | 267,531 | 275,902 |
| Interest Expense | 18,126 | 18,095 | 18,762 | 16,947 | 7,526 |
| Other Income | 15,995 | 23,752 | 29,517 | -1,666 | -19,858 |
| Pre-tax Income | 466,875 | 557,132 | 348,329 | 248,918 | 248,518 |
| Income Tax | 149,986 | 113,041 | 66,735 | 46,789 | -154,192 |
| Net Income Continuous | 316,889 | 444,091 | 281,594 | 202,129 | 402,710 |
| Net Income | $316,889 | $444,091 | $281,594 | $202,129 | $402,710 |
| EPS Basic Total Ops | 2.64 | 3.50 | 2.13 | 1.48 | 2.86 |
| EPS Basic Continuous Ops | 2.64 | 3.50 | 2.13 | 1.48 | 2.86 |
| EPS Diluted Total Ops | 2.56 | 3.43 | 2.10 | 1.44 | 2.74 |
| EPS Diluted Continuous Ops | 2.56 | 3.43 | 2.10 | 1.44 | 2.74 |
| EPS Diluted Before Non-Recurring Items | 3.81 | 3.97 | 2.50 | 2.08 | 1.86 |
| EBITDA(a) | $561,267 | $629,219 | $423,415 | $326,117 | $284,798 |